Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonas Bergh

Showing results (31-40 of 294) with videos related to

Pageof 30
Sort By:
Therapeutic Drug Monitoring|May 27, 2003
Doxorubicin-resistant, MRP1-expressing U-1285 cells are sensitive to idarubicinKerstin Jönsson-Videsäter, Göran Andersson, Jonas Bergh, et al.
Histopathology|December 11, 2013
Low concordance of biomarkers in histopathological and cytological material from breast cancerGustav Stålhammar, Gustaf Rosin, Irma Fredriksson, et al.
Acta Oncologica (Stockholm, Sweden)|November 11, 2014
A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, SwedenLuisa Kessler, Claudette Falato, Sara Margolin, et al.
Acta Oncologica (Stockholm, Sweden)|July 26, 2006
Improvements in patient satisfaction at an outpatient clinic for patients with breast cancerMia Bergenmar, Urban Nylén, Elisabet Lidbrink, et al.
Pharmacogenomics|September 11, 2018
Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patientsSarah Sim, Jonas Bergh, Mats Hellström, et al.
Acta Oncologica (Stockholm, Sweden)|February 18, 2011
Tailored chemotherapy doses based on toxicity in breast cancer result in similar quality of life values, irrespective of given dose levelsMariann Iiristo, Tom Wiklund, Nils Wilking, et al.
British Journal of Cancer|April 27, 2016
Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancerElin Sjöberg, Martin Augsten, Jonas Bergh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2016
Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?Antroula Papakonstantinou, Theodoros Foukakis, Kenny A Rodriguez-Wallberg, et al.
Cancers|May 8, 2019
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer ImmunotherapySebastian Chrétien, Ioannis Zerdes, Jonas Bergh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Reply to A.Y. LinAntroula Papakonstantinou, Theodoros Foukakis, Kenny A Rodriguez-Wallberg, et al.
Pageof 30

Showing results (31-40 of 294) with videos related to

Sort By:
Pageof 30
Therapeutic Drug Monitoring|May 27, 2003
Doxorubicin-resistant, MRP1-expressing U-1285 cells are sensitive to idarubicinKerstin Jönsson-Videsäter, Göran Andersson, Jonas Bergh, et al.
Histopathology|December 11, 2013
Low concordance of biomarkers in histopathological and cytological material from breast cancerGustav Stålhammar, Gustaf Rosin, Irma Fredriksson, et al.
Acta Oncologica (Stockholm, Sweden)|November 11, 2014
A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, SwedenLuisa Kessler, Claudette Falato, Sara Margolin, et al.
Acta Oncologica (Stockholm, Sweden)|July 26, 2006
Improvements in patient satisfaction at an outpatient clinic for patients with breast cancerMia Bergenmar, Urban Nylén, Elisabet Lidbrink, et al.
Pharmacogenomics|September 11, 2018
Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patientsSarah Sim, Jonas Bergh, Mats Hellström, et al.
Acta Oncologica (Stockholm, Sweden)|February 18, 2011
Tailored chemotherapy doses based on toxicity in breast cancer result in similar quality of life values, irrespective of given dose levelsMariann Iiristo, Tom Wiklund, Nils Wilking, et al.
British Journal of Cancer|April 27, 2016
Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancerElin Sjöberg, Martin Augsten, Jonas Bergh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2016
Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?Antroula Papakonstantinou, Theodoros Foukakis, Kenny A Rodriguez-Wallberg, et al.
Cancers|May 8, 2019
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer ImmunotherapySebastian Chrétien, Ioannis Zerdes, Jonas Bergh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Reply to A.Y. LinAntroula Papakonstantinou, Theodoros Foukakis, Kenny A Rodriguez-Wallberg, et al.
Pageof 30